IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis
Public ClinicalTrials.gov record NCT06677710. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1B Study of IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Refractory Primary and Secondary Progressive Multiple Sclerosis
Study identification
- NCT ID
- NCT06677710
- Recruitment status
- Suspended
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Indapta Therapeutics, INC.
- Industry
- Enrollment
- 34 participants
Conditions and interventions
Conditions
- Autoimmune Diseases
- Autoimmune Diseases of the Nervous System
- Demyelinating Autoimmune Diseases, Central Nervous System (CNS)
- Demyelinating Diseases
- Immune System Diseases
- Multiple Sclerosis
- Nervous System Diseases
- Non-Active SPMS
- Non-Active Secondary Progressive Multiple Sclerosis
- Primary Progressive Multiple Sclerosis (PPMS)
- Secondary Progressive Multiple Sclerosis (SPMS)
Interventions
- Cyclophosphamide Drug
- Fludarabine Drug
- IDP-023 Drug
- Interleukin-2 Drug
- Mesna Drug
- Ocrelizumab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 29, 2026
- Primary completion
- Dec 30, 2026
- Completion
- Dec 30, 2028
- Last update posted
- Apr 29, 2025
2026 – 2028
United States locations
- U.S. sites
- 5
- U.S. states
- 5
- U.S. cities
- 5
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Stanford University | Stanford | California | 94305 | — |
| University of Colorado Hospital | Aurora | Colorado | 80045 | — |
| AdventHealth Orlando - Adventist Health System/Sunbelt, Inc. | Orlando | Florida | 32803 | — |
| Kansas University Medical Center | Kansas City | Kansas | 66160 | — |
| Washington University in St. Louis | St Louis | Missouri | 63130 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06677710, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 29, 2025 · Synced Apr 29, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06677710 live on ClinicalTrials.gov.